Stockreport

Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch® to Treat Migraines

Tonix Pharmaceuticals Holding Corp.  (TNXP) 
Last tonix pharmaceuticals holding corp. earnings: 3/24 05:15 pm Check Earnings Report
US:NASDAQ Investor Relations: tonixpharma.com
PDF New patent expected to provide market exclusivity into 2036 Zembrace® SymTouch® (sumatriptan succinate injection) 10mg is indicated for the acute treatment of migraine [Read more]